Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Carlos Escobar Cervantes1*, Julio Martí-Almor2, Alejandro Isidoro Pérez Cabeza3,4, Kevin Bowrin5, Aleix Llorac Moix6, Mar Genís Gironès6, David Gasche7, Aurélie Millier8, Jean Tardu8, Mondher Toumi9, Jean-Baptiste Briere10

1 Servicio de Cardiología, Hospital La Paz, Madrid, Spain, 2 Servicio de Cardiología, Hospital del Mar, Barcelona, Spain, 3 Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain, 4 Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, 5 Bayer plc, Reading, Berkshire, United Kingdom, 6 Bayer Hispania, Barcelona, Spain, 7 Real-World Evidence Solutions, IQVIA, Madrid, Spain, 8 Creativ-Ceutical, Paris, France, 9 Aix-Marseille University, Marseille, France, 10 Bayer AG, Berlin, Germany

* escobar_cervantes_carlos@hotmail.com

Abstract

Aims

A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with non-valvular atrial fibrillation in Spain.

Methods

All inputs were derived from real-world studies: baseline patient characteristics, clinical event rates, as well as persistence rates for the vitamin K antagonist treatment option. A meta-analysis of real-world studies provided treatment effect and persistence data for rivaroxaban, dabigatran and apixaban, each compared with vitamin K antagonist therapy. The model considered 3-month cycles over a lifetime horizon. The model outcomes included different costs, quality-adjusted life years and life-years gained. Sensitivity analyses were performed to test the robustness of the model.

Results

When compared with vitamin K antagonist, rivaroxaban incurred incremental costs of €77 and resulted in incremental quality-adjusted life years of 0.08. The incremental cost per quality-adjusted life year was €952. For the same comparison, the incremental cost per quality-adjusted life year for dabigatran was €4,612. Finally, compared with vitamin K antagonist, the incremental cost per quality-adjusted life year for apixaban was €32,015. The sensitivity analyses confirmed the robustness of the base case results. The probabilities to be cost-effective versus vitamin K antagonist were 94%, 86% and 35%, respectively, for rivaroxaban, dabigatran and apixaban, considering a willingness-to-pay threshold of €22,000.
per quality-adjusted life year gained, based on a cost-effectiveness study of the Spanish National Health System.

**Conclusion**

These results suggest that rivaroxaban and dabigatran are cost-effective versus vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation, from the Spanish National Health System perspective.

**Introduction**

Atrial fibrillation (AF), the most common cardiac arrhythmia, is recognised as the primary cause of stroke, which is considered the most serious of embolic events. Patients with AF are about five times more likely to have a stroke compared with those without AF [1]. AF is the result of abnormal electrical activity disrupting the rhythm of the heart, resulting in symptoms such as chest pain, palpitations, dyspnoea, dizziness and syncope [2,3]. It is estimated to have a prevalence of 3% in the general population, which, alongside the increased risk of stroke and death associated with AF, results in significant clinical and economic burdens [4,5].

The risk of stroke and death associated with AF can be reduced with anticoagulation. Therefore, anticoagulation with a vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulant (NOAC) is now recognised as an important part of the treatment strategy in these patients [6–9]. There are limitations associated with VKA therapy, including variability in the effect related to clinical and/or genetic factors, drug and certain food interactions, and the need for frequent routine monitoring. Poor anticoagulation control with a VKA is associated with a higher risk of both thromboembolic and haemorrhagic complications [10].

In the last decade, NOACs have emerged as an alternative for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), and clinical practice guidelines generally recommend NOACs over VKA for stroke prevention in these patients [3,11]. However, due to cost concerns, the Spanish Medicine Agency Therapeutic Positioning Report positions the NOACs as second-line therapy following VKAs, and only as a first-line therapy in certain situations [12].

Both economic and clinical evaluations are needed when Health Technology Assessment bodies make decisions regarding the reimbursement of new technologies [13–16]. Economic evaluations include cost-effectiveness models that use efficacy data to demonstrate clinical benefits, with most data originating from randomised controlled trials (RCTs) [17]. This is because RCT data are often the only data available at the time of model development, but real-world evidence (RWE) is now playing an increasingly large role in the process [14,16,18]. RWE is associated with limitations when compared with RCTs, in terms of the interpretation of results and the ability to account for potential biases, but it also offers several advantages over RCTs. For example, RWE is able to capture data on the routine care of a patient population in the real world, rather than the selected populations included in RCTs. RWE studies generally also have large sample sizes and are, therefore, able to provide different insights compared with the smaller sample sizes of RCTs. Finally, RWE can provide data on more outcomes for longer follow-up periods compared with RCTs, which usually have short- to medium-term follow-up periods and focus on a small number of outcomes [13,16]. RWE is, therefore, able to inform cost-effectiveness models on the real-world use and costs of a drug, including whether the label-recommended dose is used [14].
This paper aims to assess the cost-effectiveness of three different NOACs (rivaroxaban, dabigatran and apixaban) compared with VKA for stroke prevention in patients with NVAF in the Spanish healthcare setting, considering RWE exclusively. The results of our analysis demonstrate that, based on RWE, rivaroxaban and dabigatran are cost-effective options versus VKA for stroke prevention in NVAF from the Spanish National Health System perspective with a threshold of €22,000 per quality-adjusted life year (QALY) gained.

Methods

Model overview

An updated international Markov model was used to assess the cost-effectiveness of three NOACs (rivaroxaban, dabigatran and apixaban), each compared with VKA, for the first-line treatment of stroke in adult patients with NVAF and more than one risk factor for stroke [19]. The cost-effectiveness analysis was conducted from the Spanish National Health System perspective with a lifetime horizon (30 years simulated).

The latter simulates various health states based on NVAF potential complications (stable AF, acute and post-major ischaemic stroke, acute and post-minor ischaemic stroke, acute and post-myocardial infarction (MI), acute and post-intracranial haemorrhage and gastrointestinal bleeding), and the absorbing health state of death. It is assumed that during each Markov cycle of 3 months, a patient can stay within the same health state or change to a different one. Patients transition through the model, accumulating QALYs associated with each different health state, costs of pharmacological treatment, drug administration and management of clinical events. Regarding the treatment allocation, a patient can discontinue his/her initial treatment, switch from a NOAC to VKA, switch from one VKA to another VKA, or stop treatment, i.e. switch from any treatment to no treatment. The Markov model was designed to simulate long-term clinical and economic consequences up to death, or until occurrence of a subsequent event, independent of the treatment. The model outcomes included the number of different clinical events (ischaemic stroke, MI and bleeds), as well as the total QALYs, the total life-years gained (LYG), the total costs and the incremental cost per QALY or per LYG. Both health outcomes and costs were discounted at 3% per annum as recommended from the Spanish National Health System perspective [20].

Model input parameters

Three clinical experts in stroke prevention in patients with NVAF validated the model design, the data sources (i.e. various RWE studies) and the input values used in the analysis, in a consensus meeting. All inputs are presented in Tables 1 and 2.

Patient population. The analysis considered patients with characteristics drawn from a recent Spanish RWE study in order to ensure generalisability to the NVAF population in Spain [21]. The mean age of the patient population at model entry was 73.4 years, of which 51.7% were male. Moreover, 17.8% had an intermediate CHA2DS2-VASc score (0–1) and 82.2% had a high CHA2DS2-VASc score (≥2).

Clinical event rates. The baseline 3-month probabilities of the VKA arm were derived from existing Spanish RWE studies, which provided event rates for ischaemic stroke, gastrointestinal bleeding and intracranial haemorrhage [21]; no Spanish input was retrieved for MI, so an existing systematic review was considered [23]. The split between minor and major ischaemic stroke was derived from another RWE study conducted in the US [22]. Moreover, the risk for minor and major ischaemic stroke was adjusted by age using results from the RWE Framingham Heart Study, in order to correctly reflect the increased stroke risk, positively related with the age of the simulated patient cohort [40]. The treatment effect for each NOAC was
Table 1. Model inputs.

| Value Range Used in DSA | Distribution Used in PSA | Source |
|-------------------------|--------------------------|--------|
| 3-month probabilities (VKA arm) (derived from baseline event rates per 100 patients-years) |
| Minor IS 0.114% [0.100%; 0.130%] Beta | Weighted average of event rates identified in Giner-Soriano et al. 2017 [21] + Hylek et al. 2003 [22] |
| Major IS 0.163% [0.144%; 0.187%] Beta |
| MI 0.193% [0.181%; 0.205%] Beta | Weighted average of event rates identified in Briere et al. 2019 [23] |
| GI bleeding 0.260% [0.225%; 0.297%] Beta | Weighted average of event rates identified in Giner-Soriano et al. 2017 [21] |
| ICH 0.085% [0.072%; 0.132%] Beta |
| 3-month probabilities of discontinuation |
| 0–3 months 15.00% [14.19%; 15.81%] Beta | De Andres-Nogales et al. 2015 [24] |
| 3–6 months 10.59% [9.89%; 11.28%] Beta |
| 6–12 months 8.23% [7.61%; 8.85%] Beta |
| 12+ months 6.40% [5.86%; 6.95%] Beta |
| Baseline event rates per 100 patient-years (VKA arm) |
| IS 1.11 [0.98; 1.27] - | Giner-Soriano et al. 2017 [21] |
| GI bleeding 1.04 [0.90; 1.19] - |
| ICH 0.34 [0.29; 0.53] - |
| MI 0.77 [0.73; 0.82] - | Briere et al. 2019 [23] |
| Proportion of switch |
| VKA 25.80% [21.93%; 29.67%] Beta | Johnson et al. 2016 [25] |
| Rivaroxaban 23.20% [19.72%; 26.68%] Beta |
| Dabigatran 35.40% [30.09%; 40.71%] Beta |
| Apixaban 36.70% [31.20%; 42.21%] Beta |
| Hazard ratio (rivaroxaban arm) |
| Minor IS 0.83 [0.75; 0.93] Beta | Coleman et al. 2019 [26] |
| Major IS Beta |
| MI 0.96 [0.80; 1.14] Beta |
| GI bleeding 1.22 [1.12; 1.33] Beta |
| ICH 0.68 [0.52; 0.90] Beta |
| Discontinuation 0.62 [0.60; 0.65] Beta |
| Hazard ratio (dabigatran arm) |
| Minor IS 0.79 [0.65; 0.97] Beta | Coleman et al. 2019 [26] |
| Major IS Beta |
| MI 0.84 [0.71; 1.00] Beta |
| GI bleeding 1.12 [1.02; 1.24] Beta |
| ICH 0.45 [0.36; 0.58] Beta |
| Discontinuation 0.91 [0.53; 1.24] Beta |
| Hazard ratio (apixaban) |
| Minor IS 1.01 [0.87; 1.17] Beta | Coleman et al. 2019 [26] |
| Major IS Beta |
| MI 1.00 N/A - |
| GI bleeding 0.52 [0.38; 0.70] Beta |
| ICH 0.41 [0.28; 0.60] Beta |
| Discontinuation 1.08 [0.81; 1.45] Beta |

In-hospitalisation mortality rates per clinical event in the model (Continued)
### Table 1. (Continued)

| Event                                      | Value         | Range Used in DSA | Distribution Used in PSA | Source                                      |
|--------------------------------------------|---------------|-------------------|--------------------------|---------------------------------------------|
| **3-month probabilities (VKA arm)**       |               |                   |                          |                                             |
| Minor IS                                  | 2.89%         | [2.57%; 3.20%]    | Beta                     | Rubio-Terrés et al. 2016 [27]               |
| Post-minor IS                             | N/A           | N/A               | -                        |                                             |
| Major IS                                  | 12.60%        | [9.40%; 15.70%]   | Beta                     |                                             |
| Post-major IS                             | 2.63%         | [0.91%; 13.50%]   | Beta                     |                                             |
| MI                                         | 9.69%         | [7.27%; 12.11%]   | Beta                     |                                             |
| Post-MI                                    | 2.68%         | [0.00%; 6.75%]    | Beta                     |                                             |
| ICH                                        | 38.85%        | [29.14%; 48.56%]  | Beta                     |                                             |
| Post-ICH                                   | 2.63%         | [0.91%; 13.50%]   | Beta                     |                                             |
| GI bleeding                                | 7.33%         | [6.92%; 7.74%]    | Beta                     | Ministerio de Sanidad, 2017 [28]           |
| **Utility values**                         |               |                   |                          |                                             |
| Stable AF                                  | 0.73          | [0.71; 0.75]      | Beta                     | Sullivan et al. 2011 [29]                  |
| Minor IS                                   | 0.73          | [0.55; 0.91]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| Major IS                                   | 0.41          | [0.31; 0.51]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| Post-minor IS                              | 0.76          | [0.57; 0.95]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| Post-major IS                              | 0.56          | [0.42; 0.70]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| MI                                         | 0.66          | [0.53; 0.79]      | Beta                     | Pocket 2014 et al. [31]                    |
| Post-MI                                    | 0.73          | [0.58; 0.88]      | Beta                     | Pocket 2014 et al. [31]                    |
| ICH                                        | 0.56          | [0.45; 0.67]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| Post-ICH                                   | 0.67          | [0.54; 0.80]      | Beta                     | Luengo-Fernandez et al. 2013 [30]          |
| GI bleeding                                | 0.70          | [0.56; 0.84]      | Beta                     | Sullivan et al. 2011 [29]                  |
| **Resource use and costs (€2018)**         |               |                   |                          |                                             |
| **Daily treatment cost**                   |               |                   |                          |                                             |
| VKA                                        | 0.10          | N/A               | -                        | CGCOF, 2019 [32]                           |
| Rivaroxaban                                | 1.79          | N/A               | -                        |                                             |
| Dabigatran                                 | 1.79          | N/A               | -                        |                                             |
| Apixaban                                   | 1.79          | N/A               | -                        |                                             |
| **IS costs**                               |               |                   |                          |                                             |
| Acute treatment (minor)                    | 5,258         | [3,953; 6,572]    | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| Acute treatment (major)                    | 7,208         | [5,406; 9,010]    | Gamma                    | Baron-Esquivias et al. 2015 [33]           |
| Monthly follow-up (minor)                  | 124           | [93; 156]         | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| Monthly follow-up (major)                  | 2,159         | [1,619; 2,699]    | Gamma                    | Hervas-Angulo et al. 2006 [34]             |
| Rehabilitation                             | 3,015         | [2,261; 3,768]    | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| MIA                                        | 5,174         | [3,880; 6,467]    | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| Monthly follow-up                         | 516           | [129; 215]        | Gamma                    | Escolar-Albaladejo et al. 2016 [36] Mar et al. 2011 [37] |
| **Bleeding**                               |               |                   |                          |                                             |
| Acute treatment GI bleeding (non-ICH)      | 3,579         | [2,685; 4,474]    | Gamma                    | Escolar-Albaladejo et al. 2016 [36] Monreal et al. 2009 [38] |
| Acute treatment—ICH                        | 7,793         | [5,845; 9,741]    | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| Monthly follow-up                          | 191           | [143; 238]        | Gamma                    | Alvarez-Sabin et al. 2017 [39]             |
| Rehabilitation                             | 2,874         | [2,155; 3,592]    | Gamma                    | Rubio-Terrés et al. 2016 [27]               |
| **Resource use for rehabilitation**        |               |                   |                          |                                             |

(Continued)
Discontinuation. As a patient can remain on initial treatment or discontinue in real life, the model was updated to account for discontinuation. The discontinuation risk is unlikely to be constant over time, so the model has been adapted to capture the evolution of the discontinuation with time [25]. Discontinuation was split into four periods in the model: from initiation to 3 months, from 3 months to 6 months, from 6 months to 1 year, and after 1 year. A Spanish study reported persistence rates for VKA for two periods [24], i.e. from 3 months to 6 months and from 6 months to 1 year. Assumptions were made to calculate the 3-month probabilities of discontinuation. The comparative treatment effect for each NOAC assessed in the model, compared with VKA, was taken from the previously mentioned meta-analysis [26].

Mortality. Owing to the high age of the population at model entry, a background mortality rate was applied to each health state extracted from the Spanish mortality tables [41]. In addition to the mortality of the general population, a specific mortality related to each clinical event was considered [27,28].

Utility. As too few Spanish utility values were available, only utility values from UK studies were considered [29–31,42]. It has to be noted that no treatment-related utility decrements were considered in the base case analysis.

Healthcare resource use and costs. The current analysis considered drug acquisition, administration, VKA monitoring costs and costs associated with the management of clinical events. All healthcare resource use and costs were collected from Spanish RWE studies [27,33–36,39]. All these costs were updated to 2018 values according to the Consumer Price Index [43]. Expert opinion was considered for the proportion of rehabilitation after stroke or bleeding (intracranial haemorrhage or gastrointestinal bleeding).

Table 1.  (Continued)

| Value Range Used in DSA | Distribution Used in PSA | Source |
|-------------------------|--------------------------|--------|
| % of rehabilitation for minor IS | 5.0% [4.25%; 5.75%] Beta | Experts committee |
| % of rehabilitation for major IS | 37.4% [31.79%; 43.01%] Beta | |
| % of rehabilitation for GI bleeding | 10.6% [9.01%; 12.19%] Beta | |
| % of rehabilitation for ICH | 45.0% [38.25%; 51.75%] Beta | |

DSA, deterministic sensitivity analysis; GI, gastrointestinal; ICH, intracranial haemorrhage; IS, ischaemic stroke; MI, myocardial infarction; PSA, probabilistic sensitivity analysis; VKA, vitamin K antagonist.

https://doi.org/10.1371/journal.pone.0266658.t001

Table 2. Relative risk for ischaemic strokes by age group [40].

| Age Group | Relative Risk |
|-----------|---------------|
| 55–59     | 0.667         |
| 60–64     | 0.760         |
| 65–69     | 0.854         |
| 70–74     | 1.000 (reference) |
| 75–79     | 1.146         |
| 80–84     | 1.281         |
| 85–89     | 1.480         |
| 90+       | 1.719         |

https://doi.org/10.1371/journal.pone.0266658.t002

taken from a published meta-analysis, providing hazard ratios (HRs) for all comparators versus VKA, considering RWE in both prevalent and incident populations [26].
Sensitivity analyses. In order to test the impact of variations in the parameters included in the model, a deterministic sensitivity analysis was conducted. Similarly, a probabilistic sensitivity analysis was performed to evaluate the parameter uncertainty on the cost-effectiveness results. For this analysis, it was assumed that the 3-month probabilities, proportion of switch, HRs, mortality rates, utilities and resource use for rehabilitation would be adjusted to beta distributions (parameter 0 to 1), and that resource use and costs would be adjusted to gamma distributions (0 to infinity). In addition, several specific scenarios were considered. The first scenario considers another source of RWE population characteristics with older patients (77 years old) and a more severe CHA2DS2-VASc mean score [44]. The second scenario tested different time horizons (10 and 20 years). Finally, a third scenario considered treatment effect, in terms of event reduction, based on international and Spanish RWE studies (Table 1) [26,45,46].

Results

The results for rivaroxaban, dabigatran and apixaban each compared with VKA are presented in Table 3.

Patients treated with rivaroxaban experienced incremental gains in both QALYs (0.08) and life-years (0.09) compared with VKA. Patients receiving rivaroxaban experienced fewer MIs and a lower rate of strokes and intracranial bleeds, but also experienced a higher rate of gastrointestinal bleeds. However, these incremental differences between rivaroxaban and VKA were minimal. The final benefits were translated into an incremental cost-effectiveness ratio (ICER) of €952 per QALY gained and an ICER of €828 per LYG. The ICER for dabigatran versus VKA was €4,612 per QALY gained, and the ICER for apixaban versus VKA reached €32,015 per QALY gained. For dabigatran, incremental gains in both QALYs (0.07) and life-years (0.08) compared with VKA were observed, while QALY gains of 0.03 and LYG 0.04 were observed for apixaban.

Table 3. Model results.

| Outcome                        | VKA Value | Rivaroxaban Value | Incr. vs VKA | Dabigatran Value | Incr. vs VKA | Apixaban Value | Incr. vs VKA |
|--------------------------------|-----------|-------------------|--------------|------------------|--------------|---------------|--------------|
| Costs (€)                      |           |                   |              |                  |              |               |              |
| Drug acquisition costs         | 145       | 2,711             | 2,566        | 2,024            | 1,879        | 1,741          | 1,596        |
| Drug administration costs      | 1,345     | 928               | −417         | 917              | −427         | 887           | −458         |
| Clinical event management costs| 18,818    | 16,745            | −2,073       | 17,667           | −1,151       | 18,634         | −184         |
| Total costs                    | 20,307    | 20,384            | 77           | 20,608           | 300          | 21,262         | 955          |
| Health benefits                |           |                   |              |                  |              |               |              |
| Total QALYs                    | 7.16      | 7.24              | 0.08         | 7.23             | 0.07         | 7.19           | 0.03         |
| Total LY                       | 9.96      | 10.06             | 0.09         | 10.04            | 0.08         | 10.00          | 0.04         |
| Ischaemic strokes              | 0.29      | 0.26              | −0.03        | 0.28             | −0.02        | 0.29           | 0.00         |
| Myocardial infarctions         | 0.14      | 0.12              | −0.02        | 0.13             | −0.01        | 0.14           | 0.00         |
| ICH                            | 0.02      | 0.02              | 0.00         | 0.01             | −0.01        | 0.01           | −0.01        |
| GI bleeding                    | 0.05      | 0.07              | 0.02         | 0.06             | 0.01         | 0.04           | −0.01        |

Incremental costs-effectiveness ratios (€)

- Incremental cost/QALY: 952, 4,612, 32,015
- Incremental cost/LYG: 828, 3,800, 24,572

Data are rounded to the nearest € for costs and to two decimal places for health benefits.

GI, gastrointestinal; ICH, intracranial haemorrhage; LY, life year; LYG, life-year gained; QALY, quality-adjusted life year; VKA, vitamin K antagonist.

https://doi.org/10.1371/journal.pone.0266658.t003
Rivaroxaban is, therefore, associated with the lowest incremental cost and the highest effectiveness in terms of LYG and QALY gained versus VKA, mainly due to a reduction in stroke rate which resulted in a lower ICER versus VKA in comparison with dabigatran and apixaban. These results suggest that rivaroxaban is the most cost-effective option versus VKA.

The main drivers of the ICERs for rivaroxaban, dabigatran and apixaban, each compared with VKA, are presented in Figs 1–3. The Tornado diagrams show that the results were robust to plausible changes in the parameter values; some parameters cross into negative ICER values, showing that the model is sensitive to the choice of parameter value. The main drivers identified were major stroke and post-major stroke mortality probabilities, as well as major stroke follow-up costs for the analysis of rivaroxaban; for dabigatran, the main drivers were dabigatran maintenance, major stroke and post-major stroke mortality probabilities; in the apixaban analysis, maintenance, major stroke probability and switch proportion were identified as the main drivers. Further studies should be performed to better pinpoint the exact value of the parameters that drive the ICERs for rivaroxaban, dabigatran and apixaban.

Cost-effectiveness scatterplots for rivaroxaban, dabigatran and apixaban, each compared with VKA, are presented in Figs 4–6. There was no evidence of a correlation between incremental costs and incremental effects.

No official threshold for cost-effectiveness is available in Spain, but a recent reference suggests considering a range between €22,000 and €25,000 per QALY [47]. The probabilities for each assessed NOAC to be cost-effective compared with VKA, considering a cost-effectiveness
threshold of €22,000 per QALY, were 94%, 86% and 35% for rivaroxaban, dabigatran and apixaban, respectively.

The results of the scenarios are presented in Table 4. The first scenario considering another source of RWE population characteristics, with older patients and a more severe CHA2DS2-VASc mean score [44], showed an increased ICER to €3,625 per QALY gained for rivaroxaban, to €6,787 per QALY gained for dabigatran and to €40,864 per QALY gained for apixaban. The second scenario evaluated based on 10 years as the model time horizon, resulted in an increased ICER to €14,842 per QALY gained for rivaroxaban, to €13,670 per QALY gained for dabigatran and to €51,297 per QALY gained for apixaban. The analysis with a 20-year time horizon increased the ICER to €1,079 per QALY gained for rivaroxaban, to €4,696 per QALY gained for dabigatran and to €32,566 per QALY gained for apixaban. The third scenario conducted, considering HRs derived from Spanish RWE studies [27,45,46], yielded an ICER of €598 for rivaroxaban, of €21,986 per QALY for dabigatran and of €23,241 for apixaban.

Discussion

Although fewer MIs and strokes should be balanced with an increased number of bleeds, the results highlight that rivaroxaban and dabigatran are cost-effective versus VKA for stroke prevention in adult patients with NVAF in the Spanish healthcare setting. The reduction in clinical events such as stroke, the avoided costs associated with lower hospital admissions, lower rehabilitation proportion and no requirement of international normalised ratio monitoring, likely offsets the economic burden of NOACs. The results also suggest that rivaroxaban is the
most cost-effective alternative; the level of stroke prevention results in a lower incremental cost and higher effectiveness versus VKA, as this is a key driver of the ICER. While apixaban was associated with fewer bleeds, the rates of MI and ischaemic stroke were simulated almost similar to VKA, as a result of quasi-neutral HRs. As per the high management cost of these two events, a strong impact on ICER is observed.

RCTs have already shown that NOACs are at least as effective as VKAs for stroke prevention in patients with NVAF [48–51], and existing cost-effectiveness analyses in literature have also found NOACs to be cost-effective in Spain [27,33,52] and in Europe [53–55]. Of note, Baron Esquivias et al. [33] showed that apixaban was cost-effective versus acenocoumarol in the Spanish healthcare setting, while the results of the present analysis are less favourable. However, the results of all these cost-effectiveness analyses, including the one from Baron Esquivias et al., were all based on treatment effects coming from clinical trials [27,33,52]. The disparities between these studies could be related to the appropriateness of the apixaban dose used in clinical practice, which may differ among the studies.

The main strength and added value of the present analysis is the full integration of RWE for the clinical input variables of the model. This provides more generalisable information on patient population characteristics and addresses several gaps related to the treatment effect. In real life, rivaroxaban was associated with a higher effectiveness than apixaban versus VKA for stroke prevention [26]. The difference in the results identified can be explained by confounding in a non-randomised comparison, but are more likely explained by an effect already well...
recognised in clinical practice: inadequate NOAC use at reduced doses is associated with a slightly better safety profile, but with a noticeable reduction in the effectiveness of stroke prevention [56,57]. Another explanation for these results could be that proposed by Fernández et al. 2020, who suggested that those NOACs with simpler dosage adjustment (by only one adjustment criterion–renal function, such as for rivaroxaban) could be correlated with less probability of dosage error by physicians and, therefore, with fewer thromboembolic events rates in real life [58]. This suggests that reduced doses of NOACs should only be used when indicated according to drug labelling and not when physicians perceive an increased risk of bleeding. Unfortunately, inappropriate drug use is frequent [59–61] and apixaban underdosing has worse effectiveness than other NOACs (rivaroxaban, dabigatran) in routine clinical practice [56,57].

The model structure of this cost-effectiveness analysis was based on the previous submission of rivaroxaban to the National Institute for Health and Care Excellence (NICE) in the UK [7], and although no major criticism has been raised by the evidence review group, several adjustments were implemented in order to integrate RWE. The initial population is based on an RWE study [21], to reflect characteristics of patients with AF in Spain. The progression of patients between states is done via transition probabilities derived from RWE, both for event
rates for VKA, and for treatment effects [21–24]. The treatment effects were indeed taken from RWE meta-analyses performed for each drug separately versus VKA [26]. Costs and utilities were also derived from existing RWE studies [27,29–39]. It is worth noting that all key cost-effectiveness drivers of economic models submitted to NICE, including discontinuation rates, cost of international normalised ratio monitoring visits with VKA treatment, and patient baseline age were identified in RWE sources in the current model.

Several limitations must be presented. First, launched in Spain in 2016, edoxaban has not been assessed in the current analysis due to the paucity of RWE studies published in the literature so far. Second, the use of RWE in a meta-analysis may introduce a bias relative to residual confounding; however, this limitation was discussed previously and considered controlled, as per the stability of the results when scenarios were conducted [62]. Third, although all studies used to populate this model were drawn from RWE, Spanish sources could not be retrieved for all of them, but efforts were made to identify similar European studies. As an example, no MI rates for VKA and no utility values were available in Spain, and the inputs were drawn from a UK RWE study [23,29–31]. All three clinical experts agreed on this methodology where no Spanish data could be found and validated every input value taken from those European RWE studies. Lastly, gastrointestinal bleeding data were used as a proxy for major bleeding, but this assumption was acceptable in the rivaroxaban NICE evaluation [7].
Table 4. Scenario results.

| Scenario                                                                 | Incremental cost-effectiveness ratios/QALY (€) |
|--------------------------------------------------------------------------|-----------------------------------------------|
|                                                                          | Rivaroxaban | Dabigatran | Apixaban |
| 1: RWE population characteristics with older patients (77 years old) and | Increase vs VKA | Increase vs VKA | Increase vs VKA |
| a more severe CHA2DS2-VASc mean score [44]                               | 3,625       | 6,787      | 40,864    |
| 2: Different time horizons [44]                                           |             |            |           |
| 10 years                                                                 | 14,842      | 13,670     | 51,297    |
| 20 years                                                                 | 1,079       | 4,696      | 32,566    |
| 3: Treatment effect, in terms of event reduction, based on RWE studies   | 598         | 21,986     | 23,241    |

QALY, quality-adjusted life year; RWE, real-world evidence; VKA, vitamin K antagonist.

https://doi.org/10.1371/journal.pone.0266658.t004
Conclusions
This RWE economic analysis suggests that rivaroxaban and dabigatran should be considered as cost-effective options versus VKA for stroke prevention in patients with NVAF in the Spanish healthcare setting. Rivaroxaban proved to be the most cost-effective alternative versus VKA, with an ICER of €952 per QALY gained. Rivaroxaban was followed by dabigatran with an ICER versus VKA of €4,612 per QALY gained, while apixaban resulted in an ICER versus VKA of €32,015 per QALY gained, which was above the cost-effectiveness threshold generally accepted in Spain. The results of this economic evaluation are reasonably robust, given the extensive sensitivity analyses conducted.

These findings provide valuable insights into real-world economic value of interventions, supporting the implementation of less restrictive use conditions for NOACs for stroke prevention in patients with NVAF in Spain.

Author Contributions
Conceptualization: Carlos Escobar Cervantes.
Data curation: Carlos Escobar Cervantes.
Formal analysis: Carlos Escobar Cervantes.
Funding acquisition: Carlos Escobar Cervantes.
Investigation: Carlos Escobar Cervantes.
Methodology: Carlos Escobar Cervantes.
Project administration: Carlos Escobar Cervantes.
Resources: Carlos Escobar Cervantes.
Software: Carlos Escobar Cervantes.
Supervision: Carlos Escobar Cervantes.
Validation: Carlos Escobar Cervantes.
Visualization: Carlos Escobar Cervantes.
Writing – original draft: Carlos Escobar Cervantes.
Writing – review & editing: Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere.

References
1. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33: 2719–2747. https://doi.org/10.1093/eurheartj/ehs253 PMID: 22922413
2. Bunch TJ, Gersh BJ. Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J Gen Intern Med. 2011; 26: 531–537. https://doi.org/10.1007/s11606-010-1574-8 PMID: 21108047
3. Hindricks G, Piotara T, Dages N, Arbeo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42: 373–498. https://doi.org/10.1093/eurheartj/ehaa812 PMID: 32860505
4. Bajpai A, Camm AJ, Savelieva I. Epidemiology and economic burden of atrial fibrillation. US Cardiology Review. 2007; 4: 4–17.

5. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011; 14: 65–74. https://doi.org/10.3111/13696998.2010.546465 PMID: 21222564

6. National Institute for Health and Care Excellence. Darbigratran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Technology appraisal guidance [TA249]. 2012. Available from: http://www.nice.org.uk/ta249. Accessed 15 December 2021.

7. National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. Technology appraisal guidance [TA256]. 2012. Available from: http://www.nice.org.uk/ta256. Accessed 15 December 2021.

8. National Institute for Health and Care Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Technology appraisal guidance [TA275]. 2013. Available from: http://www.nice.org.uk/guidance/TA275. Accessed 15 December 2021.

9. Kirchhof P, Benussi S, Kotecha D, Aholeson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893–2962. https://doi.org/10.1093/eurheartj/ehw210 PMID: 27567408

10. Gallagher AM, Setakis E, Plumb JM, Clements A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011; 106: 968–977. https://doi.org/10.1160/TH11-05-0353 PMID: 21901239

11. January CT, Wann LS, Alkins H, Chen LY, Cigarroa JE, Cleveland JC Jr., et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140: e125–e151. https://doi.org/10.1161/CIR.000000000000665 PMID: 30686041

12. Agencia Española de Medicamentos y Productos Sanitarios. Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. [Document #UT_ACOD/VS/21112016]. 2016. Available from: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-ora les.pdf. Accessed 15 December 2021.

13. Blommeinstein HM, Franken MG, Uyl-de Groot CA. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry. Pharmacoconomics. 2015; 33: 551–560. https://doi.org/10.1007/s40273-015-0260-4 PMID: 25644460

14. Garrison LP Jr., Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007; 10: 326–335. https://doi.org/10.1111/j.1524-4733.2007.00186.x PMID: 17888097

15. Makady A, Ham RT, de Boer A, Hillege H, Kluengel O, Goetsch W, et al. Policies for use of real-world data in Health Technology Assessment (HTA): a comparative study of six HTA agencies. Value Health. 2017; 20: 520–532. https://doi.org/10.1016/j.jval.2016.12.003 PMID: 28407993

16. Annemans L, Kubin M. Real-life data: a growing need. ISPOR Connections. 2007; 13: 8–13.

17. Bowrin K, Briere JB, Fauchier L, Coleman C, Millier A, Toumi M, et al. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS One. 2020; 15: e0295301. https://doi.org/10.1371/journal.pone.0295301 PMID: 31978044

18. Campbell JD, McQueen RB, Briggs A. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014; 11 Suppl 2: S105–111. https://doi.org/10.1513/AnnalsATS.201309-295RF PMID: 24559022

19. Rubio-Ternés C, Codes R, Rubio-Rodriguez D. Cost-effectiveness analysis of rivaroxaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain. J Health Econ Outcomes Res. 2016; 4: 19–34.

20. Lopez-Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010; 11: 513–520. https://doi.org/10.1007/s10198-010-0244-4 PMID: 20405159

21. Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, Castells X, Capellà D, Ferreira-Gonzalez I, et al. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Pharmacoepidemiol Drug Saf. 2017; 26: 97–107. https://doi.org/10.1002/pds.4137 PMID: 27868275
22. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349: 1019–1026. https://doi.org/10.1056/NEJMoa022913 PMID: 12968085

23. Briere JB, Bowrin K, Coleman C, Fauchier L, Levy P, Folkerks K, et al. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2019; 19: 27–36. https://doi.org/10.1080/14737167.2018.1518134 PMID: 30169975

24. de Andrés-Nogales F, Oyagüez I, Betegón-Nicolás L, Canal-Fontcuberta C, Soto-Alvarenga de Soto-A. Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. Rev Clin Esp. 2015; 215: 73–82. https://doi.org/10.1016/j.rce.2014.08.008 PMID: 25288530

25. Johnson ME, Lefèvre C, Collins SL, Evans D, Kloss S, Ridha E, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016; 6: e011471. https://doi.org/10.1136/bmjopen-2016-011471 PMID: 27678530

26. Coleman CI, Briere JB, Fauchier L, Levy P, Bowrin K, Tourmi M, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 2019; 7: 1574541. https://doi.org/10.1080/20016689.2019.1574541 PMID: 30774786

27. Rubio-Terrés CC, Rubio-Rodríguez D. Cost-effectiveness analysis of apixaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain. J Health Econ Outcomes Res. 2016; 4: 19–34.

28. Ministerio de Sanidad Consumo y Bienestar Social. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. 2017 Available from: https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbd.htm. Accessed 15 December 2021.

29. Sullivan PW, Steijko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom and the United States of America: October 2011. Value Health. 2014; 17: A328. https://doi.org/10.1016/j.jval.2014.08.598 PMID: 27200555

30. Luengo-Fernández R, Bull L, Welch S, Cuthbertson F, Rothwell PM, et al. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology. 2013; 81: 1588–1595. https://doi.org/10.1212/01.wnl.0000433335.61603.07 PMID: 24107865

31. Pocock RD, McEwan P, Beckham C, Shutler S, Martin S, Yousef Z, et al. Health utility in patients following cardiovascular events. Value Health. 2014; 17: A328. https://doi.org/10.1016/j.jval.2014.08.598 PMID: 27200555

32. Consejo General de Colegios Oficiales de Farmacéuticos. BotPLUS 2—Base de datos de medicamentos. 2019 Available from: https://botplusweb.portalfarma.com. Accessed 15 December 2021.

33. Barón Esquivias G, Escolar-Albaladejo G, Zamorano JL, Betegón-Nicolás L, Canal-Fontcuberta C, de Salas-Cansado M, et al. Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. J Health Econ Outcomes Res. 2016; 4: 19–34.

34. Hervas-Angulo A, Cabases-Hita JM, Forcen-Alonso T. Costs deriving from strokes from a social perspective. A retrospective incidence approach with a follow-up at three years. Rev Neurol. 2006; 43: 518–525. PMID: 17072806

35. Restovic G, Carcedo D, McLeod EJ, Guillemín ALG, Evers T. PCV72 cost-effectiveness of rivaroxaban versus acenocoumarol in the stroke prevention in patients with non-valvular atrial fibrillation in the spanish setting. 2012; 15: A375.

36. Escolar-Albaladejo G, Barón-Esquivias G, Zamorano JL, Betegón-Nicolás L, Canal-Fontcuberta C, de Salas-Cansado M, et al. Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain. Atención Primaria. 2016; 48: 394–405. https://doi.org/10.1080/14737167.2015.1102682 PMID: 25183216

37. Mar J, Arrospide A, Begiristain JM, Larranaga I, Elosegui E, Oliva-Moreno J. The impact of acquired brain damage in terms of epidemiology, economics and loss in quality of life. BMC Neurol. 2011; 11: 46. https://doi.org/10.1186/1471-2377-11-46 PMID: 21496356

38. Monreal M, Gonzalez-Rojas N, Vieta A, Wolowacz SE. Análisis económico de dabigatran etexilato en prevención primaria del tromboembolismo venoso tras artroplastia total de cadera o rodilla. PharmacoEconomics Spanish Research Articles. 2009; 6: 126–145.

39. Alvarez-Sabin J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017; 18: 449–458. https://doi.org/10.1007/s10198-016-0799-9 PMID: 27084749
40. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290: 1049–1056. https://doi.org/10.1001/jama.290.8.1049 PMID: 12941677

41. World Health Organization. Global Health Observatory data repository, Life tables by country (Spain). 2016 Available from: http://apps.who.int/gho/data/view.main.LT62210?lang=en. Accessed 15 December 2021.

42. Gage BF, Cardinali AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996; 156: 1829–1836. PMID: 8790077

43. Spanish National Statistics Institute. Consumer Price Index at constant taxes. 2020 Available from: https://www.ine.es/dynt3/inbase/index.htm?padre=579&capsel=578. Accessed 15 December 2021.

44. Barrios V, Escobar C, Prieto L, Osorio G, Polo J, Lobos JM, et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Rev Esp Cardiol (Engl Ed). 2015; 68: 769–776. https://doi.org/10.1016/j.rec.2015.04.017 PMID: 26169326

45. Escobar C, Martí-Almor J, Pérez Cabeza A, Martínez-Zapata MJ. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2019; 72: 305–316. https://doi.org/10.1016/j.rec.2018.03.009 PMID: 29606361

46. Monreal-Bosch M, Soulard S, Crespo B, Brand S, Kansal A. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain]. Rev Neurrol. 2017; 64: 247–256. PMID: 28272725

47. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018; 27: 746–761. https://doi.org/10.1002/hec.3633 PMID: 29282798

48. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in nonvalvular atrial fibrillation (RE-LY trial). N Engl J Med. 2009; 361: 1139–1151. https://doi.org/10.1056/NEJMoa090561 PMID: 19717844

49. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27: 949–953. https://doi.org/10.1093/eurheartj/ehi825 PMID: 16527828

50. Patil MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Apixaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 893–902. https://doi.org/10.1056/NEJMoa1009638 PMID: 21830957

51. Patil MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–891. https://doi.org/10.1056/NEJMoa1009638 PMID: 21830957

52. González-Juanatey JR, Álvarez-Sabin J, Lobos JM, Martínez-Rubio A, Reverter JC, Oyague I, et al. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed). 2012; 65: 901–910. https://doi.org/10.1016/j.recesp.2012.06.006 PMID: 22958943

53. Ferreira J, Mirco A. Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Rev Port Cardiol. 2015; 34: 179–191. https://doi.org/10.1016/j.rep.2014.08.008 PMID: 25727748

54. Janzic A, Kos M. Cost-effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015; 33: 395–408. https://doi.org/10.1007/s40273-014-0246-7 PMID: 25512096

55. Bennaghmouch N, de Veer A, Mahmoodi BK, Jore-Bonet M, Lip GYH, Bode K, et al. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands. Eur Heart J Qual Care Clin Outcomes. 2019; 5: 127–135. https://doi.org/10.1093/eurheartj/ehz003 PMID: 30016398

56. Nielsen PB, Skjøth F, Sagaard M, Kjældgaard JN, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017; 356: j510. https://doi.org/10.1136/bmj.j510 PMID: 28188243

57. Yao X, Shah N, Sangaralingham LR, Gersh B, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017; 69: 2779–2790. https://doi.org/10.1016/j.jacc.2017.03.600 PMID: 28596892

58. Fernández CS, Guillón A, Formiga F. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2020; 9: 509–523. https://doi.org/10.2217/ceq-2019-0197 PMID: 32329353

59. Basaran O, Filiz Basaran N, Cekic EG, Altun I, Dogan V, Mert GO, et al. PRRescriptOn:PrescriptOn PatelERNs of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost. 2017; 23: 384–391. https://doi.org/10.1177/1076029615614395 PMID: 26519049
60. Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother. 2014; 48: 1258–1268. https://doi.org/10.1177/1060028014540868 PMID: 24982310

61. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017; 10: 87–94. https://doi.org/10.2147/IJGM.S129235 PMID: 28331354

62. Briere JB, Wu O, Bowrin K, Millier A, Toumi M, Taieb V, et al. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2019; 35: 1867–1872. https://doi.org/10.1080/03007995.2019.1647020 PMID: 31328580